|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Cripto-1 and OCT4, expressed in stem cells and cancers, play important roles in tumorigenesis.
|
29223130 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Furthermore, during ethanol-induced cellular transformation, cells gained the phenotypes of cancer stem cells (CSCs) by expressing pluripotency maintaining factors (Oct4, Sox2, cMyc and KLF4) and stem cell markers (CD24, CD44 and CD133).
|
29761897 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The activated p-AKT enhances SOX2 and OCT4 activity and thereby maintains cancer cell stemness.
|
29477378 |
2018 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells were analyzed using the marker Oct-4 to improve an understanding of the proliferative ability of cancer stem cells under various pathological conditions, which may lead to the development of novel cancer therapeutics.
|
29142598 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line.
|
28454439 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The results suggest that transplantation of such in vitro enriched and expanded OCT4-specific CD8+ CIK cells may improve the specific immune defense mechanism against cancer stem cells, providing a novel avenue of cancer stem cell targeted immunotherapy for clinical treatment of ovarian cancer.
|
28426690 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Treatment of tumor-bearing mice with genotoxic chemotherapy not only prolonged survival and reduced tumor size but also selectively eliminated the OCT4-positive cancer stem cells.
|
29141221 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Oct4 was reported to be one of the most important pluripotency transcription factors in the biology of stem cells including cancer stem cells, and progressed malignant cells.
|
28426762 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
A similar treatment also modulated numerous microRNAs (miRs) including one regulator of Oct4 as well as miRs involved in oncogenesis and/or malignancy, with only a few estrogen-induced miRs.
|
27959387 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Cancer Stem Cells (CSCs), which in some cases express markers of pluripotency (e.g., Oct-4), share many of the molecular features of normal stem cells.
|
27730468 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
The gene and protein expression levels of pluripotent stem cell markers (Tra-1-60, Oct4, Nanog) and cancer stem cell markers (CD133, CD44) were up-regulated in transduced Rbc51 cells compared to control cells.
|
27856246 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Expression of the cancer stem cell markers ABCG2 and OCT-4 in right-sided colon cancer predicts recurrence and poor outcomes.
|
28212529 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
The cell viability of mammospheres were evaluated by MTT assay and the OCT4 expression, a cancer stem cells marker, was verified by immunocitochemistry.
|
27671309 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Octamer-binding transcription factor 4 (Oct4) protein, encoded by the POU class 5 homeobox 1 gene, is important in maintaining self-renewal of pluripotent stem cells, and is closely associated with cancer.
|
28123573 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Here, we initially showed that HBV stimulates the production of cancer stem cells (CSCs)-related markers (CD133, CD117 and CD90) and CSCs-related genes (Klf4, Sox2, Nanog, c-Myc and Oct4) and facilitates the self-renewal of CSCs in human hepatoma cells.
|
28455240 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Real-time PCR was used to determine the expression levels of several reported cancer stem cell (CSC) markers, including CD44, CD133, ALDH1 and OCT4, in three OSCC cell lines.
|
28215944 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In agreement, we find that FUT9 silencing decreases the expression of the colorectal cancer TIC marker CD44 and the level of the OCT4 transcription factor, which is known to support cancer stemness.
|
29196508 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
PosttranslationalModification |
BEFREE |
BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
|
28645561 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Cancer stem cells (CSCs) are responsible for the resistance of osteosarcoma to chemotherapy and OCT4, SOX2 and SSEA4 have been used to identify CSCs in osteosarcoma.
|
28934267 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
Expression of Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas.
|
26945449 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Bmi-1, CD133, Nanog and Oct-4 have been reported as cancer stem cell (CSC) markers in head and neck squamous cell carcinoma (HNSCC).
|
28220856 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Tumorspheres derived from epidermal growth factor receptor (EGFR)-mutant HCC827 and EGFR wild-type A549 cells expressing higher cancer stemness markers (CD133, Oct4, and Nanog) were used as cancer stemness models.
|
28787001 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
siRNA-mediated knockdown of ID1 disrupts Nanog- and Oct-4-mediated cancer stem cell-likeness and resistance to chemotherapy in gastric cancer cells.
|
28529558 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
Biomarker |
BEFREE |
Finally, we analyzed the expression and clinical significance of epithelial-to-mesenchymal transition (EMT) markers (E-cadherin and N-cadherin) and cancer stem cell (CSC) markers (Nanog, Oct-4, and Sox-2) in CRC tissues.
|
29081665 |
2017 |
|
POU5F1P4
|
Malignant Neoplasms
|
0.100 |
AlteredExpression |
BEFREE |
In this review, the existence of crosstalks in the signaling pathways between Raf-kinase inhibitor protein and several cancer stem cell transcription factors (Oct4, KLF4, Sox2 and Nanog) was assembled.
|
28378634 |
2017 |